BioSpace News Archive

A large international study led by deCODE Genetics on the genetics of migraine provides novel insights into the biology of migraine enabling detection of rare variants protecting against migraine, opening an avenue for potential development of novel drug targets.

Epic Bio is presenting new data reflecting advances in its Gene Expression Modulation System (GEMS) platform, alongside additional preclinical data supporting the company’s lead program, EPI-321, in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD).

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the development of its next-generation mRNA-launched enveloped virus-like particle (eVLP) technology, which expands on the company’s current proprietary eVLP technology by coding the particles in messenger RNA (mRNA).

SEED Therapeutics Inc. announced at its Monday, October 23, 2023 Targeted Protein Degradation (TPD) Think Tank symposium that it had successfully discovered a ST-00937, a new chemical entity (NCE) molecular glue that has already achieved IND Candidate status and will be advanced for the treatment of cancers in SEED’s first IND filing, as early as 2024.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2023 financial results via press release before the market opens on Tuesday, November 7, 2023.

Sonoma Pharmaceuticals, Inc. today announced the pricing of its public offering of 8,500,000 shares of common stock at a price of $0.20 per share.

The extraordinary general meeting in Orexo AB on 26 October 2023 resolved, in accordance with the nomination committee’s proposal, that the number of board members shall be eight with no deputy board members.

Chime Biologics, a leading CDMO that enables its partners’ success in biologics, and Hope Medicine Inc. (HopeMed), a science-driven, patient-centric, clinical-stage biotech company, announced on September 28 that the companies are collaborating to develop and manufacture the first-in-class monoclonal antibody drug HMI-115.

elo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo”) is pleased to announce that it has passed all requirements and received its Certificate of Accreditation of ISO 15189.

Celltrion USA, Inc. (Celltrion USA) today announced its FDA-approved biosimilar, YUFLYMA® (adalimumab-aaty), has been added to CarePartners Specialty Pharmacy Cost Savings Programs.